Conflict-driven posture and energy shocks dominate today's outlook: Poland seals border airspace and crude holds near $92 as the Middle East and Russia-Ukraine wars grind on, while Washington moves to formalize defense-AI rules. Beneath the headlines, structural forces hold — coal's decline resists subsidy, Putin preserves succession ambiguity, and Blackstone's redemption gate is more likely to contain stress than collapse into a full suspension.

Adjacent-indication expansion is a standard pharma playbook for post-inflection blockbusters, and announcing or registering a trial is far easier than approval, lowering the bar for resolution. The Biotech chain's dominant interpretation ('Biotech Innovation Breakthroughs', 35%, cancer pipeline acceleration 80%) supports this. The Skeptic passed it but noted the evidence shows rising optimism rather than confirmed program intent, capping confidence. The technologist is my best-calibrated agent (Brier 0.03) with a slight under-prediction bias, so I hold near the analyst's 0.66 and nudge to 0.67. Key uncertainty is whether a *new, dedicated oncology-labeled* program (not just exploratory commentary) appears within exactly 180 days.